Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study

The Lancet Respiratory Medicine 2026

View at publisher
Authors: Jonathan H. Rayment, Gwyneth Davies, Jonathan M. Gaffin, Jordana E. Hoppe, Ajay S. Kasi, Marcus A Mall, Edward F. McKone, Bonnie W. Ramsey, Jennifer L Taylor, Elizabeth Tullis, Emily McDougall, Robin Pottackal
+29 more Rachel Zahigian, Katie Krone, Mark Jennings, James F. Chmiel, Gary McPhail, Erica Roesch, Daniel Weiner, Carlos Milla, Jessica Pittman, Rachel Linnemann, Hugo Escobar, Fadel Ruiz, Thomas Lahiri, Brooke Moore, Alexander Moeller, Anna‐Maria Dittrich, Felix Ratjen, Pornchai Tirakitsoontorn, Maria Dowell, Lena Thia, Catherine Byrnes, Florian Stehling, Isabelle Sermet‐Gaudelus, Philippe Reix, Philip Robinson, Claire Wainwright, David Graeme Hancock, Andrew Tai, Isabelle de Monestrol
DOI: 10.1016/s2213-2600(26)00257-2
Cited by: 1
References: 33

Fields of Study & Subjects

Cystic Fibrosis Research Advances Pharmaceutical studies and practices Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Publication date
1 September 2026
Language
EN